The newly funded projects focus on the development of informatics infrastructure for sharing genomic and clinical data to better manage patient care.
Most recently, Celgene has licensed the GNS platform for internal use and made an undisclosed equity investment in the company.
Six combinations of two aligners and three variant callers tested for the study offered similar results with some variation in computational costs.
T2 said it's in a strong position to achieve planned portfolio milestones over the next two years, including submitting its next test for FDA clearance next year.
The firm plans to launch a test based on an miRNA signature for commercial use within Europe in 2018, after which it intends to seek FDA clearance.
The test is based on a biomarker signature that consists of a core set of 31 genes associated with endotoxin tolerance in sepsis patients.
The launch follows a beta that kicked off earlier this year to put the software through its paces with data curators and other scientists.
The developer has presented clinical results that provide a base for completing development of a multi-protein test kit and conducting a clinical trial in advance of FDA submission.
The Centre for Drug Research and Development has spun out the company to develop a rapid detection test based on the body's immune response.
HudsonAlpha researchers are expected to sequence 20,000 patient tumor and non-tumor samples for ORIEN's Avatar initiative by 2019.
In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.
Technology Review points out that a new US presidential science advisor hasn't been selected.
Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.